Cullinan Therapeutics Shares Preclinical Data for CLN-978
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) presented new preclinical data for CLN-978 at ACR Convergence 2025.
CLN-978 showed rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases.
- Presentation at American College of Rheumatology (ACR) Convergence 2025
- Poster presentation session on October 28, 10:30 a.m.-12:30 p.m. CT (Poster Session C, Poster Number 2293)
- Booth (#1074) in the Exhibit Hall
CLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases
Cullinan Therapeutics is a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer.
Author summary: Cullinan Therapeutics presents preclinical data for CLN-978.
More News
- The Founding of New York - Historic UK
- Leptin neural circuit restores balance after anxiety upsets it
- Pirates Listed as Potential Fit for Trent Grisham, Luis Arráez and Other Top Free Agents
- The environmental impact of the 2026 World Cup
- Liam Hemsworth vs. Gabriella Brooks: Who Has the Higher Net Worth?
- Queer Issues are Human Issues - The McGill Daily
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- Three resilient UK multinationals global managers are excited about | Trustnet
- Jensen Ackles back on 'Tracker' 3.2 to amp up the suspense
- Novartis Enters $12 Billion Definitive Merger Agreement to Acquire Avidity Biosciences | PharmExec